EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

Midori Shima, Kagehiro Amano, Yoshiyuki Ogawa, Koichiro Yoneyama, Ryoto Ozaki, Ryota Kobayashi, Emiko Sakaida, Makoto Saito, Takashi Okamura, Toshihiro Ito, Norimichi Hattori, Satoshi Higasa und 3 weitere

Journal of Thrombosis and Haemostasis · 2023-03 · 21 (3) · 534-545

DOI: 10.1016/j.jtha.2022.10.004 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-03. Verfasst von Midori Shima und 14 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan; Department of Pediatrics, Nara Medical University, Kashihara, J…. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chugai Pharmaceutical Co Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Emicizumab is a bispecific antibody that mimics the cofactor function of activated factor (F) VIII. It prevents bleeds in patients with congenital hemophilia A regardless of the inhibitor status; however, no prospective clinical studies have been conducted for emicizumab in patients with acquired hemophilia A (PwAHA). OBJECTIVES: To describe the primary analysis results from a prospective, multicenter, open-label phase III study evaluating the efficacy, safety, and pharmacokinetics of emicizumab in PwAHA (AGEHA; JapicCTI-205151). METHODS: Emicizumab was administered subcutaneously at 6 mg/kg on day 1 and 3 mg/kg on day 2, followed by 1.5 mg/kg once weekly from day 8 onward. Predefined criteria for the completion of dosing included FVIII activity of >50 IU/dL. RESULTS: By the cutoff date (April 23, 2021), 12 patients on immunosuppressive therapy were enrolled, and 11 of them (91.7%) completed emicizumab treatment. The mean trough plasma emicizumab concentration rapidly reached a steady state (1 week), achieving the efficacious level that was established in patients with congenital hemophilia A (>30 μg/mL). Before first emicizumab administration, 7 patients (58.3%) experienced 77 major bleeds. During emicizumab treatment, no major bleeds occurred in any patient. Neither death due to bleeding or infection nor any study treatment-related serious adverse event was reported. One asymptomatic, nonserious deep vein thrombosis was discovered with no laboratory findings indicating any trend toward hypercoagulation. CONCLUSION: These results suggest that emicizumab prophylaxis with the tested dosing regimen and completion criteria may have a favorable benefit-risk profile in PwAHA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, BispecificHumansFactor VIIIHemorrhageAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

bispecific monoclonal antibodiesemicizumabfactor VIII deficiency, acquiredprophylaxisprospective studies

Substanzen

Factor VIIIAntibodies, BispecificemicizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan; Department of Pediatrics, Nara Medical University, Kashihara, Japan. Electronic address: mshima@naramed-u.ac.jp.
  • Department of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan.
  • Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Chugai Pharmaceutical Co Ltd, Tokyo, Japan.
  • Department of Hematology, Chiba University Hospital, Chiba, Japan.
  • Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.

Förderung

  • Chugai Pharmaceutical Co Ltd

Zitieren

APA

Shima, M., Amano, K., Ogawa, Y., Yoneyama, K., Ozaki, R., Kobayashi, R., Sakaida, E., Saito, M., Okamura, T., Ito, T., Hattori, N., Higasa, S., Suzuki, N., Seki, Y., & Nogami, K. (2023). A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. Journal of Thrombosis and Haemostasis, 21(3), 534-545. https://doi.org/10.1016/j.jtha.2022.10.004

Vancouver

Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R, et al. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. Journal of Thrombosis and Haemostasis. 2023;21(3):534-545. doi:10.1016/j.jtha.2022.10.004

BibTeX
@article{Shima2023,
  author = {Shima, Midori and Amano, Kagehiro and Ogawa, Yoshiyuki and Yoneyama, Koichiro and Ozaki, Ryoto and Kobayashi, Ryota and Sakaida, Emiko and Saito, Makoto and Okamura, Takashi and Ito, Toshihiro and Hattori, Norimichi and Higasa, Satoshi and Suzuki, Nobuaki and Seki, Yoshinobu and Nogami, Keiji},
  title = {A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  volume = {21},
  number = {3},
  pages = {534--545},
  doi = {10.1016/j.jtha.2022.10.004}
}
Kostenlos starten →